Tecogen (TGEN) director receives 25,000-share stock option award at $5.17
Rhea-AI Filing Summary
Tecogen Inc. director Angelina Galiteva reported an equity compensation grant in the form of a stock option. She received options to buy 25,000 shares of common stock at an exercise price of $5.17 per share, vesting 25% per year.
The options become exercisable starting on June 26, 2027 and expire on June 26, 2036. After this grant, she holds stock options covering 25,000 underlying shares directly. This is a compensation-related award, not an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Galiteva Angelina
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 25,000 | $5.17 | $129K |
Holdings After Transaction:
Stock Option (Right to Buy) — 25,000 shares (Direct)
Footnotes (1)
- F1. Vests 25% per year
Key Figures
Option grant size: 25,000 shares
Exercise price: $5.17 per share
Underlying shares: 25,000 shares
+3 more
6 metrics
Option grant size
25,000 shares
Stock Option (Right to Buy) grant to director
Exercise price
$5.17 per share
Conversion or exercise price for option grant
Underlying shares
25,000 shares
Common Stock underlying the stock option
Post-grant derivative holdings
25,000 options
Total derivative securities following transaction
Exercise start date
June 26, 2027
Option exercise date
Expiration date
June 26, 2036
Option expiration date
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, conversion or exercise price, Vests 25% per year
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
conversion or exercise price financial
"conversion_or_exercise_price: "5.1700""
Vests 25% per year financial
"footnote: "Vests 25% per year""
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Tecogen (TGEN) director Angelina Galiteva report?
Angelina Galiteva reported receiving a stock option grant for 25,000 underlying Tecogen common shares. The options are a compensation-related award rather than an open-market trade, giving her the right to buy shares at a fixed exercise price of $5.17.
What are the key terms of Angelina Galiteva’s Tecogen (TGEN) stock option grant?
The grant covers 25,000 underlying common shares at a $5.17 exercise price. The options vest 25% per year, become exercisable starting June 26, 2027, and expire on June 26, 2036, providing long-dated equity incentives tied to Tecogen’s stock performance.
Is Angelina Galiteva’s Form 4 transaction in Tecogen (TGEN) a buy or a sale?
The Form 4 shows an acquisition via a stock option grant, not a market buy or sale. The transaction is coded as a grant or award, giving her derivative rights to purchase 25,000 Tecogen shares at a fixed $5.17 exercise price in the future.
How many Tecogen (TGEN) options does Angelina Galiteva hold after this transaction?
After the transaction, Angelina Galiteva holds stock options covering 25,000 underlying Tecogen common shares directly. These options vest over time and expire on June 26, 2036, aligning her potential future ownership with the company’s long-term performance.
How does the vesting work for Angelina Galiteva’s Tecogen (TGEN) option grant?
The stock option grant vests at a rate of 25% per year. This means portions of the 25,000 underlying shares become exercisable gradually over four years, encouraging ongoing board service and long-term alignment with Tecogen shareholder interests.